Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.

Ohtsu, A; Baba, H; Sakata, Y; Mitachi, Y; Horikoshi, N; Sugimachi, K; Taguchi, T

Ohtsu, A; Baba, H; Sakata, Y; Mitachi, Y; Horikoshi, N; Sugimachi, K; Taguchi, T.

Affiliation

Ohtsu A; Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa, Japan.

Br J Cancer ; 83(2): 141-5, 2000 Jul.

Article in En | MEDLINE | ID: mdl-10901361

Subject(s)

Antimetabolites, Antineoplastic/therapeutic use; Colorectal Neoplasms/drug therapy; Oxonic Acid/therapeutic use; Pyridines/therapeutic use; Tegafur/therapeutic use; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic/adverse effects; Colorectal Neoplasms/mortality; Colorectal Neoplasms/pathology; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid/adverse effects; Pyridines/adverse effects; Survival Rate; Tegafur/adverse effects; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxonic Acid / Pyridines / Colorectal Neoplasms / Tegafur / Antimetabolites, Antineoplastic Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2000 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google